Details of the Drug Combinations

General Information of This Drug (ID: DMM39BF)

• Drug Name: Mitoxantrone (DMM39BF)
• Synonyms: DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)

Indication

Acute myelogenous leukaemia; ICD 11: 2A41; Status: Approved [1]; Adult acute monocytic leukemia; ICD 11: N.A.; Status: Approved [1]; Leukemia; ICD 11: N.A.; Status: Approved [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Approved [2]; Non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Phase 1/2 [3]; Metastatic prostate carcinoma; ICD 11: N.A.; Status: Investigative [1]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Mitoxantrone + Panobinostat	DCVJ4H4	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cladribine + Mitoxantrone	DCV2945	Cladribine	Acute Lymphoblastic Leukemia	[5]
Clofarabine + Mitoxantrone	DCPIVXM	Clofarabine	Acute Lymphoblastic Leukemia	[6]
Docetaxel + Mitoxantrone	DCVRZZ6	Docetaxel	Prostate Cancer	[7]
Flavopiridol + Mitoxantrone	DCPHSFU	Flavopiridol	Adult Acute Megakaryoblastic Leukemia (M7)	[8]
Flavopiridol + Mitoxantrone	DCXLGKE	Flavopiridol	Recurrent Adult Acute Lymphoblastic Leukemia	[9]
Mitoxantrone + Capecitabine	DC1VIXA	Capecitabine	Breast Cancer	[10]
Mitoxantrone + Cytarabine	DCTOKF2	Cytarabine	Adult Acute Megakaryoblastic Leukemia (M7)	[11]
Mitoxantrone + Azacitidine	DC6TUBF	Azacitidine	Adult Acute Megakaryoblastic Leukemia (M7)	[12]
Etoposide + Mitoxantrone	DCXEHDI	Etoposide	Adult Acute Megakaryoblastic Leukemia (M7)	[13]
Flavopiridol + Mitoxantrone	DC2VD8I	Flavopiridol	Adult Acute Basophilic Leukemia	[14]
Flavopiridol + Mitoxantrone	DC8MWRX	Flavopiridol	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	[15]
Flavopiridol + Mitoxantrone	DCX5ANI	Flavopiridol	Acute Myeloid Leukemia	[16]
Mitoxantrone + Daunorubicin	DCUTFEA	Daunorubicin	Acute Myeloid Leukemia (AML)	[17]

References

• [1] Mitoxantrone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] ClinicalTrials.gov (NCT01513603) Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
• [6] ClinicalTrials.gov (NCT01842672) Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
• [7] ClinicalTrials.gov (NCT00017563) Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
• [8] ClinicalTrials.gov (NCT00470197) Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
• [9] ClinicalTrials.gov (NCT00016016) Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
• [10] ClinicalTrials.gov (NCT06156761) Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
• [11] ClinicalTrials.gov (NCT01801046) Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
• [12] ClinicalTrials.gov (NCT01839240) Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
• [13] ClinicalTrials.gov (NCT00634244) Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• [14] ClinicalTrials.gov (NCT00407966) Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• [15] ClinicalTrials.gov (NCT00795002) Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• [16] ClinicalTrials.gov (NCT02520011) Alvocidib Biomarker-driven Phase 2 AML Study
• [17] ClinicalTrials.gov (NCT02198482) Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)